- Active, not recruiting
NCT03110562 : Phase 3 - Bortezomib, Selinexor, and Dexamethasone in Patients With Myeloma (BOSTON)
Updated: Sep 22, 2022
BOSTON Study
This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (VelcadeĀ®) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple myeloma (MM) regimens. Crossover from the Vd Arm to a treatment that includes selinexor (i.e., SVdX or SdX) will be allowed at the point of IRC-confirmed objective disease progression per the IMWG criteria for patients in the Vd Arm.
Sponsor
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT03110562
Official Title: A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
First Posted: April 12, 2017
Click here for details on ClinicalTrials.gov
Dexamethasone : National Cancer Institute
Dexamethasone : MedlinePlus Drug Information
Bortezomib : National Cancer Institute
Bortezomib : MedlinePlus Drug Information
Selinexor : National Cancer Institute
Selinexor : MedlinePlus Drug Information
Drug: Selinexor
Drug: Bortezomib
Drug: Dexamethasone
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
Lancet; Nov. 2020
https://pubmed.ncbi.nlm.nih.gov/33189178/
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Am J Hematol; June 2021
https://pubmed.ncbi.nlm.nih.gov/34062004/
457 Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature
Program: Oral and Poster Abstracts
Type: Oral
Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Multiple Myeloma and Waldenstrom Macroglobulinemia: Exploring Biomarkers in the Era of Personalized Medicine
Hematology Disease Topics & Pathways:
Translational Research
Sunday, December 12, 2021: 12:00 PM
NEWTON, Mass., Nov. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI)
Total of 17 Abstracts Selected for Presentation at the Meeting, Including Five Oral Presentations
Title: Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature
Presenter: Paula Restrepo, Icahn School of Medicine at Mount Sinai
Abstract #: 457
Session Type: Oral Presentation
Session: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Multiple Myeloma and Waldenstrom Macroglobulinemia: Exploring Biomarkers in the Era of Personalized Medicine
Date and Time: Sunday, December 12, 2021 at 12:00 p.m. ET
Learn more:
Locations
United States, Florida
United States, Georgia
United States, Hawaii
United States, Iowa
United States, Kansas
United States, Kentucky
United States, Maryland
United States, Missouri
United States, New Jersey
United States, New York
United States, North Carolina
United States, Ohio
United States, Oklahoma
United States, Oregon
United States, South Carolina
United States, South Dakota
United States, Texas
Canada, Alberta
Canada, British Columbia
Canada, Nova Scotia
Canada, Ontario
Canada, Quebec
Canada, Saskatchewan
Australia, New South Wales
Australia, Queensland
Australia, South Australia
Australia, Victoria
Europe
United Kingdom
Austria
Belgium
Bulgaria
Czechia
France
Germany
Greece
Hungary
Italy
Poland
Romania
Serbia
Spain
Ukraine
Asia
India
Israel
Russian Federation